The company spotlighted its flagship automated immunoassay platform, AFIAS, featuring advanced diagnostic assays such as IGRA-TB for latent tuberculosis detection, PENKID for early prediction of acute kidney injury, TDM for therapeutic drug monitoring, HOMA-IR for assessing insulin resistance, and vitamin D deficiency testing. These assays are designed to deliver rapid, accurate results, addressing critical needs in clinical diagnostics.

Boditech Med also introduced its veterinary diagnostics lineup, including AFIAS-VET, an automated immunoassay system, and VETCHROMA 3, a manual alternative for point-of-care testing. The company additionally showcased UROCHROMA, a urine analysis platform, and VETCHEMIS, a whole-blood biochemistry analyzer—reinforcing its commitment to comprehensive diagnostic solutions across both human and animal health sectors.
Ahead of ADLM 2025, Boditech Med hosted its third South America Distributor Conference, further strengthening collaboration with key regional partners to support its growing footprint in Latin America.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr